Immune Correlates of Protection Induced by Virus-Like Particles Containing 2009 H1N1 Pandemic Influenza HA, NA or M1 Proteins
- PMID: 30430891
- DOI: 10.1080/08820139.2018.1544640
Immune Correlates of Protection Induced by Virus-Like Particles Containing 2009 H1N1 Pandemic Influenza HA, NA or M1 Proteins
Abstract
Influenza virus-like particle (VLPs) vaccines are a promising alternative to conventional egg-based vaccines. Evaluation of vaccine efficacy induced by HA-M1 VLPs, NA-M1 VLPs or M1 VLPs against virus challenge infection would provide important insight into vaccine design strategy. In this study, we generated VLPs containing hemagglutinin (HA), neuraminidase (NA) or M1 proteins derived from the A/California/04/09. Mice were immunized intramuscularly with HA-M1, NA-M1 or M1 VLPs and protective immunity was evaluated by assessing lung virus loads against low (5LD50) or high (100LD50) lethal dose of homologous virus challenges. High levels of virus-specific serum IgG antibody responses were induced in mice after HA-M1 VLPs immunization, whereas low or no IgG antibody responses were detected from immunization with NA-M1 VLPs or M1 VLPs, independently. Mice that were immunized with HA-M1 VLPs showed below the limit of detection on lung virus loads against low dose (5LD50) of challenge and significant reduction against high dose (100LD50) of challenge infection. Mice that were immunized with NA-M1 or M1 VLPs also displayed reduced lung viral loads compared to naïve control. In vitro cultures of cells from mouse spleen and bone marrow revealed that HA-M1 VLPs and NA-M1 VLPs induced higher levels of antibody-secreting cell (ASC) responses compared to naïve control, whereas M1 VLPs showed no ASC responses. HA-M1, NA-M1 or M1 VLPs immunization demonstrated varying degree of protection with respect to body weight changes and survival rates, which are consistent with the levels of antibody responses in sera and ASC responses from spleen and bone marrow.
Keywords: IgG antibody response; Influenza; VLPs; immune correlates; protection.
Similar articles
-
Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection.Virology. 2012 Sep 1;430(2):127-35. doi: 10.1016/j.virol.2012.05.006. Epub 2012 Jun 2. Virology. 2012. PMID: 22658901 Free PMC article.
-
Vaccine Efficacy Induced by 2009 Pandemic H1N1 Virus-Like Particles Differs from that Induced by Split Influenza Virus.Immunol Invest. 2020 Oct;49(7):781-793. doi: 10.1080/08820139.2019.1694539. Epub 2019 Nov 27. Immunol Invest. 2020. PMID: 31774021
-
Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens.Virus Res. 2015 Jan 2;195:35-42. doi: 10.1016/j.virusres.2014.09.018. Virus Res. 2015. PMID: 25312452
-
Influenza vaccines based on virus-like particles.Virus Res. 2009 Aug;143(2):140-6. doi: 10.1016/j.virusres.2009.04.005. Epub 2009 Apr 15. Virus Res. 2009. PMID: 19374929 Free PMC article. Review.
-
Platform for the generation of oral vaccines based on protozoan surface proteins.Medicina (B Aires). 2019;79(Spec 6/1):559-563. Medicina (B Aires). 2019. PMID: 31864226 Review. English.
Cited by
-
Influenza Virus-like Particle (VLP) Vaccines Expressing the SARS-CoV-2 S Glycoprotein, S1, or S2 Domains.Vaccines (Basel). 2021 Aug 18;9(8):920. doi: 10.3390/vaccines9080920. Vaccines (Basel). 2021. PMID: 34452044 Free PMC article.
-
Influenza vaccine efficacy induced by orally administered recombinant baculoviruses.PLoS One. 2020 May 27;15(5):e0233520. doi: 10.1371/journal.pone.0233520. eCollection 2020. PLoS One. 2020. PMID: 32459823 Free PMC article.
-
Neuraminidase in Virus-like Particles Contributes to the Protection against High Dose of Avian Influenza Virus Challenge Infection.Pathogens. 2021 Oct 7;10(10):1291. doi: 10.3390/pathogens10101291. Pathogens. 2021. PMID: 34684240 Free PMC article.
-
An HER2-Displaying Virus-Like Particle Vaccine Protects from Challenge with Mammary Carcinoma Cells in a Mouse Model.Vaccines (Basel). 2019 May 20;7(2):41. doi: 10.3390/vaccines7020041. Vaccines (Basel). 2019. PMID: 31137559 Free PMC article.
-
Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response.Front Immunol. 2022 May 19;13:878943. doi: 10.3389/fimmu.2022.878943. eCollection 2022. Front Immunol. 2022. PMID: 35663997 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous